Physician profile
Patrick A Rice
NPI 1932642238
$9,178.36
in general payments reported to CMS, 2019-2025
27 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $1,495 · 2023: $2,042 · 2024: $2,537 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,610 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,609.85 |
| Education | $346.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,653.72 | 2021-2025 | |
| Janssen Biotech, INC. | $1,058.84 | 2022-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $1,045.26 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $966.82 | 2021-2025 | |
| Lilly USA, LLC | $698.43 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $610.15 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $414.24 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $368.34 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $309.50 | 2022-2025 | Adbry |
| Amgen INC. | $306.33 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $304.52 | 2021-2025 | Dupixent |
| Dermavant Sciences, INC. | $269.50 | 2022-2024 | Vtama |
| Incyte Corporation | $228.33 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $164.94 | 2022-2025 | |
| Ucb, INC. | $157.98 | 2025 | Bimzelx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.08 | 2023-2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $99.45 | 2025 | |
| Mayne Pharma Commercial LLC | $84.09 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $83.90 | 2023-2025 | Zoryve |
| Lnhc, INC | $77.45 | 2025 | Zelsuvmi |
| Sanofi US Services INC. | $42.02 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $35.86 | 2022-2024 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.82 | 2023 | Arazlo |
| Verrica Pharmaceuticals INC. | $20.85 | 2024 | Ycanth |
| Epi Health, LLC | $19.88 | 2022 | |
| Genentech USA, INC. | $16.64 | 2022 | |
| Dermira, INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.